SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026
Key Highlights
- ➤QUELIMMUNE (SCD-PED) approved February 2024 for pediatric AKI with sepsis requiring RRT
- ➤QUELIMMUNE trials showed 77% survival, approximately 50% lower mortality versus historical data
- ➤SAVE Registry reported 76% survival at Days 28 and 60 among first 21 pediatric patients
- ➤NEUTRALIZE-AKI pivotal trial evaluating SCD therapy in 339 adults with ICU acute kidney injury
Expert Statements
Kevin Chung, M.D., Chief Medical Officer of SeaStar Medical
“I’m grateful to the PPETS organizers for the opportunity to participate in this important meeting”
Kevin Chung, M.D., Chief Medical Officer of SeaStar Medical
“I look forward to sharing lessons from our experience with QUELIMMUNE and discussing what we’ve learned about translating medical innovation into delivering improved outcomes to the most vulnerable patients.”
Dr. Chung to deliver an oral presentation highlighting QUELIMMUNE(®), an advanced extracorporeal therapy for critically ill pediatric patients with acute kidney injury (AKI)
DENVER, Sept. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that its Chief Medical Officer, Kevin Chung, M.D., will deliver an invited talk at the 2026 PPETS conference, hosted by Texas Children’s Hospital in Houston, Texas, October 6 - 8, 2026.
Get started
Create a free account to read the full story.